Literature DB >> 16053971

Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.

Guosheng Xiang1, Michael D Schuster, Tetsunori Seki, Piotr Witkowski, Shawdee Eshghi, Silviu Itescu.   

Abstract

OBJECTIVES: The aim of this study was to examine whether selective plasminogen activator inhibitor type 1 (PAI-1) downregulation in the acutely ischemic heart increases the myocardial microvasculature and improves cardiomyocyte (CM) survival.
BACKGROUND: Endogenous myocardial neovascularization is an important process enabling cardiac functional recovery after acute myocardial infarction. Expression of PAI-1, a potent inhibitor of angiogenesis, is induced in ischemic heart tissue.
METHODS: A sequence-specific catalytic deoxyribonucleic acid (DNA) enzyme was used to reduce PAI-1 levels in cultured endothelial cells and in ischemic myocardium. At the time of coronary artery ligation, rats were randomized into three groups, each receiving an intramyocardial injection (IMI) of a single dose at three different sites of the peri-infarct region consisting, respectively, of DNA enzyme E2 targeting rat PAI-1 (E2), scrambled control DNA enzyme (E0), or saline. Cardiomyocyte apoptosis, capillary density, and echocardiography were studied two weeks following infarction.
RESULTS: The E2 DNA enzyme, which efficiently inhibited rat PAI-1 expression in vitro, induced prolonged suppression (>2 weeks) of PAI-1 messenger ribonucleic acid and protein in rat heart tissues after a single IMI. At two weeks, hearts from experimental rats had over five-fold greater capillary density, 70% reduction in apoptotic CMs, and four-fold greater functional recovery compared with controls.
CONCLUSIONS: These results imply a causal relationship between elevated PAI-1 levels in ischemic hearts and adverse outcomes, and they suggest that strategies to reduce cardiac PAI-1 activity may augment neovascularization and improve functional recovery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16053971     DOI: 10.1016/j.jacc.2005.04.047

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

Review 1.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 2.  Genetic enhancement of stem cell engraftment, survival, and efficacy.

Authors:  Marc S Penn; Abeel A Mangi
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 3.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

4.  Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.

Authors:  Yu-Yu Yao; Hang Yin; Bo Shen; Lee Chao; Julie Chao
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

5.  The magnitude and temporal dependence of apoptosis early after myocardial ischemia with or without reperfusion.

Authors:  Christopher J French; Jeffrey L Spees; A K M Tarikuz Zaman; Douglas J Taatjes; Burton E Sobel
Journal:  FASEB J       Date:  2008-12-18       Impact factor: 5.191

6.  Knockdown of TNF-α by DNAzyme gold nanoparticles as an anti-inflammatory therapy for myocardial infarction.

Authors:  Inthirai Somasuntharam; Kevin Yehl; Sheridan L Carroll; Joshua T Maxwell; Mario D Martinez; Pao-Lin Che; Milton E Brown; Khalid Salaita; Michael E Davis
Journal:  Biomaterials       Date:  2015-12-21       Impact factor: 12.479

Review 7.  Challenges for heart disease stem cell therapy.

Authors:  Jane Hoover-Plow; Yanqing Gong
Journal:  Vasc Health Risk Manag       Date:  2012-02-17

8.  Selective inhibition of the master regulator transcription factor Egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction.

Authors:  Benjamin S Rayner; Gemma A Figtree; Tharani Sabaretnam; Ping Shang; Jawad Mazhar; James C Weaver; William N Lay; Paul K Witting; Stephen N Hunyor; Stuart M Grieve; Levon M Khachigian; Ravinay Bhindi
Journal:  J Am Heart Assoc       Date:  2013-07-31       Impact factor: 5.501

9.  Toxicogenomic analysis of mainstream tobacco smoke-exposed mice reveals repression of plasminogen activator inhibitor-1 gene in heart.

Authors:  Sabina Halappanavar; Martin R Stampfli; Lynn Berndt-Weis; Andrew Williams; George R Douglas; Carole L Yauk
Journal:  Inhal Toxicol       Date:  2009-01       Impact factor: 2.724

Review 10.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.